Page 299 - Read Online

Lei et al. J Cancer Metastasis Treat 2019;5:38 I http://dx.doi.org/10.20517/2394-4722.2019.12 Page 15 of 16

therapy responsiveness in breast cancer patients. Cancer Sci 2009;100:1012-7.
36. Moelans CB, de Weger RA, Monsuur HN, Vijzelaar R, van Diest PJ. Molecular profiling of invasive breast cancer by multiplex ligation-
dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 2010;23:1029-39.
37. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, et al. Emergence of constitutively active estrogen receptor-alpha
mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 2014;20:1757-67.
38. Schiff R, Veeraraghavan J, Fu X. Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic
strategies. Chicago, IL: AACR Annual Meeting; 2018.
39. Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, et al. Frequent ESR1 and CDK pathway copy-number alterations in
metastatic breast cancer. Mol Cancer Res 2019;17:457-68.
40. Markiewicz A, Welnicka-Jaskiewicz M, Skokowski J, Jaskiewicz J, Szade J, et al. Prognostic significance of ESR1 amplification and
ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients. PLoS One 2013;8:e72219.
41. Nielsen KV, Bent Ejlertsen, Sven Müller, Susanne Møller, Birgitte B, et al. Amplification of ESR1 may predict resistance to adjuvant
tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat 2011;127:345-55.
42. Holst F, Singer CF. ESR1-amplification-associated estrogen receptor alpha activity in breast cancer. Trends Endocrinol Metab
2016;27:751-2.
43. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast
cancer risk. J Natl Cancer Inst 1998;90:37-42.
44. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol
1999;188:237-44.
45. Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, et al. Gene amplification in ductal carcinoma in situ of the breast. Breast
Cancer Res Treat 2010;123:757-65.
46. Quenel-Tueux N, Debled M, Rudewicz J, MacGrogan G, Pulido M, et al. Clinical and genomic analysis of a randomised phase II study
evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-
positive breast cancer. Br J Cancer 2015;113:585-94.
47. Li S, Shen D, Shao J, Crowder R, Liu W, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-
cancer-derived xenografts. Cell Rep 2013;4:1116-30.
48. Aguilar H, Sole X, Bonifaci N, Serra-Musach J, Islam A, et al. Biological reprogramming in acquired resistance to endocrine therapy of
breast cancer. Oncogene 2010;29:6071-83.
49. Haddow A, Watkinson JM, Paterson E, Koller PC. Influence of synthetic oestrogens on advanced malignant disease. Br Med J
1944;2:393-8.
50. Kota K, Adam Brufsky, Steffi Oesterreich, Adrian Lee. Estradiol as a targeted, late-line therapy in metastatic breast cancer with estrogen
receptor amplification. Cureus 2017;9:e1434.
51. Magnani L, Frige G, Gadaleta RM, Corleone G, Fabris S, et al. Acquired CYP19A1 amplification is an early specific mechanism of
aromatase inhibitor resistance in ERalpha metastatic breast cancer. Nat Genet 2017;49:444-50.
52. Weis KE, Ekena K, Thomas JA, Lazennec G, Katzenellenbogen BS. Constitutively active human estrogen receptors containing amino
acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol 1996;10:1388-98.
53. Toy W, Shen Y, Won H, Green B, Sakr RA, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet
2013;45:1439-45.
54. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, et al. D538G mutation in estrogen receptor-alpha: a novel
mechanism for acquired endocrine resistance in breast cancer. Cancer Res 2013;73:6856-64.
55. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat
Genet 2013;45:1446-51.
56. Chandarlapaty S, Chen D, He W, Sung P, Samoila A, et al. Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic
breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol 2016;2:1310-5.
57. Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive
metastatic breast cancer patients receiving fulvestrant. Nat Commun 2016;7:11579.
58. Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates
evolution during therapy for metastatic breast cancer. Sci Transl Med 2015;7:313ra182.
59. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-
positive advanced breast cancer. J Clin Oncol 2016;34:2961-8.
60. Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, et al. Sensitive detection of mono-and polyclonal ESR1 mutations in
primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin Cancer Res 2016;22:1130-7.
61. Gelsomino L, Gu G, Rechoum Y, Beyer AR, Pejerrey SM, et al. Erratum to: ESR1 mutations affect anti-proliferative responses to
tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat 2017;163:639-40.
62. Harrod A, Fulton J, Nguyen VTM, Periyasamy M, Ramos-Garcia L, et al. Genomic modelling of the ESR1 Y537S mutation for
evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene 2017;36:2286-96.
63. Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, et al. Activating ESR1 mutations differentially affect the efficacy of ER antagonists.
Cancer Discov 2017;7:277-87.
64. Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1
activating mutations. Cancer Cell 2018;33:173-86.e5.
65. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell
2000;103:843-52.
66. Gates LA, Gu G, Chen Y, Rohira AD, Lei JT, et al. Proteomic profiling identifies key coactivators utilized by mutant ERalpha proteins as